Advancing Precision Medicine in High-Risk Breast Cancer: BRCA Mutations, Triple-Negative, and HR+/HER2– Subtypes - Episode 1
NATALEE and monarchE: Clinical Data Review and Insights Into Treating High-Risk HR+/HER2_ Early-Stage Breast Cancer
Panelists discuss the recent data from the NATALEE and monarchE studies, focusing on adjuvant CDK4/6 inhibitor selection for high-risk HR-positive/HER2-negative (HR+/HER2–) early breast cancer patients, and explore how to interpret the different efficacy signals, particularly the early curve separation observed in monarchE versus NATALEE.
Video content above is prompted by the following:
- Based on the monarchE and NATALEE trials, how do you approach adjuvant CDK4/6 inhibitor selection for patients with high-risk HR+/HER2– early breast cancer?
- How do you weigh the different efficacy signals between the trials, particularly the early separation of curves in monarchE versus NATALEE?
Related Content:
